�the kind of review being proposed does not, at least initially, appear to bring anything new or needed to is already a robust system of oversight,� mogulof said in the statement...
"it's a very exciting time," klugman said. "this is exactly where we would like prenatal diagnosis to go -- to be able to act on it.".
us opioid crisis hits indian pharma companies
.